Roche Holding AG (SWX:ROP)
357.80
+5.10 (1.45%)
Oct 9, 2026, 5:30 PM CET
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year. That makes Roche Holding AG the 274th largest employer in the world and 3rd in Switzerland.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
609.78K CHF
Profits / Employee
119.53K CHF
Market Cap
286.02B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novartis AG | 75,267 |
| Alcon | 25,000 |
| Lonza Group AG | 20,141 |
| Sandoz Group AG | 20,000 |
| Sonova Holding AG | 18,590 |
| Straumann Holding AG | 11,582 |
| Galderma Group AG | 7,676 |
| Galenica AG | 6,623 |
Roche Holding AG News
- 7 hours ago - Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss - Business Wire
- 1 day ago - Genentech announces FDA approval of Tecentriq combination - TheFly
- 1 day ago - FDA Approves Roche's Tecentriq-Based Regimens For Stage 3 Colon Cancer - Nasdaq
- 2 days ago - FDA Approves Genentech's Tecentriq in Combination With a Fluoropyrimidine and Oxaliplatin for the Adjuvant Treatment of a Certain Type of Stage III Colon Cancer - Business Wire
- 2 days ago - FDA approves Roche's Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer - GlobeNewsWire
- 2 days ago - FDA Approves Roche's Tecentriq for Stage III dMMR Colon Cancer, Boosting RHHBY's Growth Prospects - GuruFocus
- 2 days ago - Roche (RHHBY) Partners with Defand Therapeutics in $1 Billion Oncology Collaboration - GuruFocus
- 3 days ago - Zealand, Roche's obesity drug helps patients lose up to 9.2% weight in mid-stage trial - Reuters